Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Jude Masannat"'
Autor:
Christine H. Chung, Marcelo Bonomi, Conor E. Steuer, Jiannong Li, Priyanka Bhateja, Matthew Johnson, Jude Masannat, Feifei Song, Juan C. Hernandez-Prera, Bruce M. Wenig, Helen Molina, Joaquim M. Farinhas, Caitlin P. McMullen, J. Trad Wadsworth, Krupal B. Patel, Julie A. Kish, Jameel Muzaffar, Kedar Kirtane, James W. Rocco, Michael J. Schell, Nabil F. Saba
Publikováno v:
Cancers, Vol 13, Iss 5, p 1180 (2021)
We hypothesized the combination of cetuximab and nivolumab would improve survival in recurrent and/or metastatic (R/M) HNSCC by providing synergy in cancer control and evaluated toxicities and efficacy of the combination. Effects of sequential admini
Externí odkaz:
https://doaj.org/article/31536c5c24a340289ecb9d64780cba72
Autor:
Marcelo Bonomi, Nabil F. Saba, Michael J. Schell, James W. Rocco, Kedar Kirtane, Jameel Muzaffar, Julie A. Kish, Dong M. Shin, Joaquim M. Farinhas, Philip J. Stephens, Charlotte Kuperwasser, Sunil Kumar, Bruce M. Wenig, Helen Molina, Juan C. Hernandez-Prera, Feifei Song, Maria I. Poole, Jude Masannat, Matthew Johnson, Priyanka Bhateja, Conor E. Steuer, Jiannong Li, Christine H. Chung
Purpose:A phase II multi-institutional clinical trial was conducted to determine overall survival (OS) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) treated with a combination of cetuximab and nivolu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::228471a7da6400ba5eae079135c167d8
https://doi.org/10.1158/1078-0432.c.6532391.v1
https://doi.org/10.1158/1078-0432.c.6532391.v1
Autor:
Marcelo Bonomi, Nabil F. Saba, Michael J. Schell, James W. Rocco, Kedar Kirtane, Jameel Muzaffar, Julie A. Kish, Dong M. Shin, Joaquim M. Farinhas, Philip J. Stephens, Charlotte Kuperwasser, Sunil Kumar, Bruce M. Wenig, Helen Molina, Juan C. Hernandez-Prera, Feifei Song, Maria I. Poole, Jude Masannat, Matthew Johnson, Priyanka Bhateja, Conor E. Steuer, Jiannong Li, Christine H. Chung
Supplementary Figure from Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::586f92af58e5d9ed3482955ea46899d4
https://doi.org/10.1158/1078-0432.22486817
https://doi.org/10.1158/1078-0432.22486817
Autor:
Christine H. Chung, Juan C. Hernandez-Prera, Jose Conejo-Garcia, Bruce M. Wenig, Louis Harrison, Jimmy Caudell, J. Trad Wadsworth, Matthew B. Schabath, Erin M. Siegel, Michelle Fournier, Feifei Song, Ritu Chaudhary, Jude Masannat, Tessa van Veen, Garrick Aden-Buie, Travis A. Gerke, Aik Choon Tan, Jamie K. Teer, Xuefeng Wang, Laura Martin-Gomez, Robbert J.C. Slebos, Janis V. de la Iglesia
Purpose:Patients with head and neck squamous cell carcinoma (HNSCC) who actively smoke during treatment have worse survival compared with never-smokers and former-smokers. We hypothesize the poor prognosis in tobacco smokers with HNSCC is, at least i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68c7c2838d073ce3ceba5ee6539b5317
https://doi.org/10.1158/1078-0432.c.6528336
https://doi.org/10.1158/1078-0432.c.6528336
Autor:
Marcelo Bonomi, Nabil F. Saba, Michael J. Schell, James W. Rocco, Kedar Kirtane, Jameel Muzaffar, Julie A. Kish, Dong M. Shin, Joaquim M. Farinhas, Philip J. Stephens, Charlotte Kuperwasser, Sunil Kumar, Bruce M. Wenig, Helen Molina, Juan C. Hernandez-Prera, Feifei Song, Maria I. Poole, Jude Masannat, Matthew Johnson, Priyanka Bhateja, Conor E. Steuer, Jiannong Li, Christine H. Chung
Supplementary Table from Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27f9dd8e47f50b110590508f95c5cfc1
https://doi.org/10.1158/1078-0432.22486805
https://doi.org/10.1158/1078-0432.22486805
Autor:
Joseph W Franses, Mir Lim, Adam M Burgoyne, Kabir Mody, Jochen Lennerz, Jeremy Chang, Robin Imperial, Stacey N Dybel, Thi M Dinh, Jude Masannat, Caroline M Weipert, David Hsiehchen
Publikováno v:
The oncologist. 27(11)
Advanced hepatocellular carcinoma (HCC) is responsive to immune checkpoint inhibitors, but there are currently no known biomarkers to predict treatment benefit. Blood TMB (bTMB) estimation via circulating tumor DNA (ctDNA) profiling can provide a con
Autor:
Jude Masannat, Robbert J.C. Slebos, Nelusha Amaladas, Ritu Chaudhary, Juan C. Hernandez-Prera, Xuefeng Wang, Wenjuan Wu, Christine H. Chung, Jose R. Conejo-Garcia, Feifei Song, Keegan P McCleary-Sharpe, Aik Choon Tan, Gerald E Hall
Publikováno v:
Mol Carcinog
Prognosis for patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) remains poor. Development of more effective and less toxic targeted therapies is necessary for HNSCC patients. Checkpoint kinase 1 (CHK1) plays a vi
Autor:
Bushra Shariff, Reagan Barnett, Farshid Dayyani, Steven Brad Maron, Samuel J Klempner, Jude Masannat, Leylah Drusbosky, Rory Mcgriskin, Rutika Mehta
Publikováno v:
Journal of Clinical Oncology. 41:429-429
429 Background: Gastroesophageal cancers (GECs) are the 2nd highest cause of cancer mortality globally. Biomarkers such as MMR, PD-L1, and HER2 are critical for treatment strategies. Emerging biomarkers in late-stage clinical development include FGFR
Autor:
Louis B. Harrison, Laura Martin-Gomez, Michelle Fournier, Christine H. Chung, Jamie K. Teer, Feifei Song, Erin M. Siegel, Aik Choon Tan, Jude Masannat, Jose R. Conejo-Garcia, Matthew B. Schabath, Garrick Aden-Buie, Juan C. Hernandez-Prera, Bruce M. Wenig, Janis V. de la Iglesia, Robbert J.C. Slebos, Travis Gerke, Jimmy J. Caudell, Ritu Chaudhary, Tessa Van Veen, J. Trad Wadsworth, Xuefeng Wang
Publikováno v:
Clinical Cancer Research. 26:1474-1485
Purpose: Patients with head and neck squamous cell carcinoma (HNSCC) who actively smoke during treatment have worse survival compared with never-smokers and former-smokers. We hypothesize the poor prognosis in tobacco smokers with HNSCC is, at least
Autor:
Janis V. de la Iglesia, Robbert J.C. Slebos, Laura Martin-Gomez, Xuefeng Wang, Jamie K. Teer, Aik Choon Tan, Travis A. Gerke, Garrick Aden-Buie, Tessa van Veen, Jude Masannat, Ritu Chaudhary, Feifei Song, Michelle Fournier, Erin M. Siegel, Matthew B. Schabath, J. Trad Wadsworth, Jimmy Caudell, Louis Harrison, Bruce M. Wenig, Jose Conejo-Garcia, Juan C. Hernandez-Prera, Christine H. Chung
Publikováno v:
Clin Cancer Res
PURPOSE: Patients with head and neck squamous cell carcinoma (HNSCC) who actively smoke during treatment have worse survival compared to never-smokers and former-smokers. We hypothesize the poor prognosis in tobacco smokers with HNSCC is, at least in